Molecular Assemblies
Fully Enzymatic DNA Synthesis
Synthetic DNA is the life force driving discoveries in clinical medicine, therapeutics, agriculture, and food. The chemical DNA synthesis process on which the industry relies only produces short DNA oligonucleotides, aka oligos, (less than 200 bases) which are acceptable for PCR primers and probes, but limit researchers expanding to new applications. The chemical method is also “impure”—meaning that the final product has varied lengths, requiring purification—adding time and complexity to the whole process.
That’s why Molecular Assemblies developed the first Fully Enzymatic Synthesis™ (FES™) technology to accelerate the production of long, pure, and accurate DNA to power the next generation of DNA-based products, including CRISPR gene editing and many other tools used in research discovery, therapeutic development, and protein engineering. With FES technology, Molecular Assemblies can produce long, pure, sequence-specific, DNA sequences of greater than 300 bases.
Founded in 2013, the company shipped the first enzymatically synthesized oligos to customers generated by its FES technology through it’s Key Customer Program in March 2023. This is allowing scientists to get the exact long-length oligos they want, and Molecular Assemblies is scaling manufacturing capacity to fulfill the significant demand. In addition to CRISPR gene editing, FES technology can support molecular biology techniques including cloning and mutagenesis, gene assembly, as well as single-cell and spatial biology applications.
Phil Paik, PhD, Chief Technology Officer of Molecular Assemblies, said in a statement, “[…] our first Key Customer orders have come back extremely positively. Those projects include novel uses in CRISPR gene editing knock-ins and protein engineering enabled by our early access oligonucleotides.”
